Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells - 13/02/22
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Abstract |
Post-Covid pulmonary fibrosis is evident following severe COVID-19. There is an urgent need to identify the cellular and pathophysiological characteristics of chronic lung squeals of Covid-19 for the development of future preventive and/or therapeutic interventions. Tissue-resident memory T (TRM) cells can mediate local immune protection against infections and cancer. Less beneficially, lung TRM cells cause chronic airway inflammation and fibrosis by stimulating pathologic inflammation. The effects of Janus kinase (JAK), an inducer pathway of cytokine storm, inhibition on acute Covid-19 cases have been previously evaluated. Here, we propose that Tofacitinib by targeting the CD8+ TRM cells could be a potential candidate for the treatment of chronic lung diseases induced by acute SARS-CoV-2 infection.
El texto completo de este artículo está disponible en PDF.Graphical Abstract |
Keywords : Pulmonary fibrosis, Coronavirus, SARS-CoV-2, JAK inhibitors, Severe lung injury
Esquema
Vol 147
Artículo 112614- mars 2022 Regresar al número
Artículo precedente
- Covalent inhibitors of EZH2: Design, synthesis and evaluation
- Qiangsheng Zhang, Xinyi Chen, Xi Hu, Xianjie Duan, Guoquan Wan, Lu Li, Qiang Feng, Yiqian Zhang, Ningyu Wang, Luoting Yu
- Protective effect of Yangxue Jiedu Soup against psoriasis-like lesions by regulating TLR4/NF-κB signaling pathway mediated by secretion of exosome HSP70
- Jingjing Lv, Yan Wang, Jingna Xu, Tao Zhou, Zhaoxia Chen, Haoyu Yang, Tingting Di, Ping Li
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.